Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the world’s first quadrivalent cell-cultured influenza vaccine, SKYCellflu Quadrivalent prefilled syringe, has been approved by Indonesia’s Food and Drug Agency, BPOM (Badan Pengawas Obat dan Makanan). This marks the first time a domestically developed influenza vaccine has been licensed in Indonesia.
Indonesia, the world’s fourth most populous nation with over 280 million people, boasts Southeast Asia’s largest economy, with rapidly growing pharmaceutical market. According to global market research firm Innsight10, Indonesia´s flu vaccine market is projected to grow from USD 38.5 million (KRW 52.7 billion) in 2022 to USD 69.1 million (KRW 92.6 billion) in 2030.
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the world’s first quadrivalent cell-cultured influenza vaccine, SKYCellflu Quadrivalent prefilled syringe, has been approved by Indonesia’s Food and Drug Agency, BPOM (Badan Pengawas Obat dan Makanan). This marks the first time a domestically developed influenza vaccine has been licensed in Indonesia.
Indonesia, the world’s fourth most populous nation with over 280 million people, boasts Southeast Asia’s largest economy, with rapidly growing pharmaceutical market. According to global market research firm Innsight10, Indonesia´s flu vaccine market is projected to grow from USD 38.5 million (KRW 52.7 billion) in 2022 to USD 69.1 million (KRW 92.6 billion) in 2030.